following a full submission
ticagrelor film-coated tablets (Brilique®) are accepted for use within NHS Scotland.
Indication under review: co-administered with aspirin, for the prevention of atherothrombotic events in adult patients with acute coronary syndromes (unstable angina, non ST elevation myocardial infarction [NSTEMI] or ST elevation myocardial infarction [STEMI]); including patients managed medically, and those who are managed with percutaneous coronary intervention (PCI) or coronary artery by-pass grafting (CABG).
As dual therapy with aspirin, ticagrelor demonstrated a significant reduction in ischaemic events compared with another antiplatelet drug without significantly increasing the incidence of study-defined major bleeding.
Alternative treatments are available at a lower drug acquisition cost.
Download detailed advice147KB (PDF)
Medicine details
- Medicine name:
- ticagrelor (Brilique)
- SMC ID:
- 699/11
- Indication:
- Co-administered with aspirin, for the prevention of atherothrombotic events in adult patients with acute coronary syndromes (unstable angina, non ST elevation myocardial infarction [NSTEMI] or ST elevation myocardial infarction [STEMI]); including patients managed medically, and those who are managed with percutaneous coronary intervention (PCI) or coronary artery by-pass grafting (CABG).
- Pharmaceutical company
- AstraZeneca UK Ltd
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 09 May 2011